Improved clot dynamics in Morag's plasma TEG tracings after subcutaneous AV513 treatment. In a dose-escalation study, plasma prepared from Morag 2 hours after the last dose was evaluated for clotting. Dose-dependent reduction in TEG R time, improved angle, and enhanced clot strength is recorded in the TEG tracings. A, baseline, B, 0.03 mg/kg, C, 0.1 mg/kg, D, 0.5 mg/kg, E, 1.0 mg/kg, F, 1.5 mg/kg.